Drugs / IBR900
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05411757 | Jun 2022 → Jun 2023 | liver cancer | Shandong Public Health Clinical Center | Unknown | No outcome recorded |
| Phase 0 | NCT05271279 | Dec 2021 → Aug 2022 | lymphoma | Beijing Boren Hospital | Terminated | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07073833 | Jul 2025 → Jul 2027 expected | B-cell non-Hodgkin lymphoma | Imbioray (Hangzhou) Biomedicine Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBR900 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07073833 ↗ |
| Modality | Cell therapy | “trained immunity NK (tiNK) cell injection (IBR900)” NCT05271279 ↗ |